MetaCap

Indaptus Therapeutics (INDP) vs Lyell Immunopharma (LYEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Indaptus Therapeutics (INDP) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 52.4% versus a loss of 27.9%. Over five years, LYEL leads with a -92.6% price change compared with -98.3% for INDP. Lyell Immunopharma is the larger company by market cap ($441.8 million vs $433.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INDP+52.43%LYEL-27.86%
+168%+48%-72%
Nov 21, 20251 yearNov 20, 2026
INDP-98.22%LYEL-93.62%
+14%-45%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INDP versus LYEL key metrics
MetricINDPLYEL
Share price$2.82$13.80
Market cap$433.16M$441.82M
1-day change-9.90%+1.62%
YTD return-3.09%-55.17%
1-year return+52.43%-27.86%
5-year return-98.26%-92.59%
EPS (TTM)$-3.16$-12.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$36.00K
Revenue growth (YoY)—-40.98%
Net income (latest FY)$-20.85M$-274.45M
Operating margin—-748344.44%
Net margin—-762355.56%
52-week high$5.96$45.00
52-week low$0.92$7.20
Distance from 52-week high-52.68%-69.33%
Analyst consensus—buy
Avg. price target upside—+172.68%
Average volume712.87K174.76K
Shares outstanding153.60M32.02M
Employees5161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INDP has outperformed LYEL by 80.3 percentage points over the past year.

About Indaptus Therapeutics

INDP stock →

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Lyell Immunopharma

LYEL stock →

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

INDP vs LYEL FAQ

Which is bigger, Indaptus Therapeutics or Lyell Immunopharma?

Lyell Immunopharma (LYEL) is larger, with a market capitalization of $441.82M compared with $433.16M for Indaptus Therapeutics (INDP).

Which stock has performed better over the past year, INDP or LYEL?

INDP returned +52.43% over the past 12 months, compared with -27.86% for LYEL (price return, excluding dividends). Past performance does not predict future results.

Are Indaptus Therapeutics and Lyell Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons